Current Antidiabetic Drugs
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The oral α-glucosidase inhibitors used to treat diabetes include voglibose, miglitol, and acarbose.
“Among the oral AGIs used to treat diabetes are voglibose, miglitol, and acarbose.”
α-glucosidase inhibitors delay the absorption of carbohydrates, which lessens an increase in blood sugar levels after meals by about 3 mmol/l.
“They delay the absorption of carbohydrates, which lessens an increase in blood sugar levels after meals by about 3 mmol/l (reduced postprandial glucose).”
Acarbose is the most frequently used and researched drug in the α-glucosidase inhibitor class.
“The drug in this class that is most frequently used and researched is acarbose.”
Cites
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962 · see citing works
Type 2 Diabetes Mellitus: A Review of Current Trends
Olokoba, A. B., Obateru, O. A., & Olokoba, L. B. (2012) · Oman Medical Journal · doi:10.5001/omj.2012.68 · Cited by 1,338 · see citing works
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837 · see citing works
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818 · see citing works
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes
Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414266 · Cited by 668 · see citing works
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509 · see citing works
Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus
Watts, N. B., Bilezikian, J. P., Usiskin, K., Edwards, R., Desai, M., Law, G., & Meininger, G. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3167 · Cited by 454 · see citing works
Moretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350 · see citing works
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
Vilsbøll, T., Rosenstock, J., Yki‐Järvinen, H., Cefalu, W. T., Chen, Y., Luo, E., Musser, B., Andryuk, P. J., Ling, Y., Kaufman, K. D., et al. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01173.x · Cited by 305 · see citing works
Meta-analysis: metformin treatment in persons at risk for diabetes mellitus
Salpeter, S. R., Buckley, N. S., Kahn, J. A., & Salpeter, E. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.09.016 · Cited by 248 · see citing works
Glueck, C. J., Fontaine, R. N., Wang, P., Subbiah, M. T. R., Weber, K., Illig, E., Streicher, P., Sieve-Smith, L., Tracy, T. M., Lang, J. E., et al. (2001) · Metabolism · doi:10.1053/meta.2001.24192 · Cited by 188 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tegegne, B. A., Adugna, A., Yenet, A., Yihunie Belay, W., Yibeltal, Y., Dagne, A., Hibstu Teffera, Z., Amare, G. A., Abebaw, D., Tewabe, H., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1440456 · Cited by 61 · see citing works
- Authors
- Hossain, M. A., & Pervin, R.
- Affiliations
- Animal and Plant Quarantine Agency (KR)
- Kyungpook National University (KR)
- ORCID
- Hossain, Md. Akil
- Venue
- Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome
- Publisher
- Elsevier
- Published
- 2018
- Pages
- 455-473
- OpenAlex
- W2891249627
- Cited by
- 47
- References
- 11
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 6 · 2023: 5 · 2022: 8 · 2021: 3 · 2020: 3 · 2019: 3
- FWCI
- 13.27
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Elsevier eBooks (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- antidiabetic drugs, diabetes mellitus, DPP-4 inhibitors, metformin, sulfonylureas, hypoglycemia, meglitinides, alpha-glucosidase inhibitors, gastrointestinal adverse effects, drug safety and efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
